About: Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus
Creator	Zhao, Jincun Munster, Vincent Lu, Lu Ong, Hui Tan, Wen Yeap, Swee Ho, Chan, Woo Fuk, Jasper Kok, Lian Yeah, Chean
source	Medline; PMC
abstract	Middle East respiratory syndrome (MERS) is a deadly viral respiratory disease caused by MERS-coronavirus (MERS-CoV) infection. To date, there is no specific treatment proven effective against this viral disease. In addition, no vaccine has been licensed to prevent MERS-CoV infection thus far. Therefore, our current review focuses on the most recent studies in search of an effective MERS vaccine. Overall, vaccine candidates against MERS-CoV are mainly based upon the viral spike (S) protein, due to its vital role in the viral infectivity, although several studies focused on other viral proteins such as the nucleocapsid (N) protein, envelope (E) protein, and non-structural protein 16 (NSP16) have also been reported. In general, the potential vaccine candidates can be classified into six types: viral vector-based vaccine, DNA vaccine, subunit vaccine, nanoparticle-based vaccine, inactivated-whole virus vaccine and live-attenuated vaccine, which are discussed in detail. Besides, the immune responses and potential antibody dependent enhancement of MERS-CoV infection are extensively reviewed. In addition, animal models used to study MERS-CoV and evaluate the vaccine candidates are discussed intensively.
has issue date	2019-08-02(xsd:dateTime)
bibo:doi	10.3389/fmicb.2019.01781
bibo:pmid	31428074
has license	cc-by
sha1sum (hex)	27ee82e4db05cf49d789f25d14660daffe743cfd
schema:url	https://doi.org/10.3389/fmicb.2019.01781
resource representing a document's title	Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus
has PubMed Central identifier	PMC6688523
has PubMed identifier	31428074
schema:publication	Front Microbiol
resource representing a document's body	covid:27ee82e4db05cf49d789f25d14660daffe743cfd#body_text
is schema:about of	named entity 'VACCINE' named entity 'INFECTIVITY' named entity 'CAUSED BY' named entity 'DATE' named entity 'DEPENDENT' named entity 'REVIEWED' named entity 'CURRENT REVIEW' named entity 'BASED' named entity 'TYPES' named entity 'DUE TO' named entity 'POTENTIAL' named entity 'VIRAL VECTOR' named entity 'SPECIFIC' named entity 'STUDIES' named entity 'MERS VACCINE' named entity 'HAVE' named entity 'EFFECTIVE' named entity 'FOCUSED' named entity 'SUBUNIT VACCINE' named entity 'MIDDLE EAST RESPIRATORY SYNDROME' named entity 'INACTIVATED' named entity 'ADDITION' named entity 'IS A' named entity 'STUDY' named entity 'ENVELOPE' named entity 'GENERAL' named entity 'VITAL' named entity 'LICENSED' named entity 'VIRAL' named entity 'USED' named entity 'ENHANCEMENT' named entity 'ITS' named entity 'ANIMAL MODELS ' named entity 'CLASSIFIED' named entity 'VIRAL PROTEINS' named entity 'SEARCH' named entity 'CORONAVIRUS' named entity 'RECENT' named entity 'PROVEN' named entity 'PROTEIN ' named entity 'VIRAL DISEASE' named entity 'INFECTION' named entity 'OUR' named entity 'FAR' named entity 'PROTEIN' named entity '28S' named entity 'EVALUATE' named entity 'DNA VACCINE' named entity 'MOST RECENT' named entity 'CORONAVIRUS' named entity 'NANOPARTICLE' named entity 'TREATMENT' named entity 'NUCLEOCAPSID' named entity 'RESPIRATORY DISEASE' named entity 'VACCINE DEVELOPMENT' named entity 'MIDDLE EAST RESPIRATORY SYNDROME ' named entity 'MERS-COV' named entity 'VIRUS VACCINE' named entity 'ROLE' named entity 'TO PREVENT' named entity 'ANTIBODY' named entity 'OVERALL' named entity 'IMMUNE RESPONSES' named entity 'REPORTED' named entity 'SPIKE' named entity 'MERS' named entity 'virus' named entity 'vaccine' named entity 'MERS-CoV' named entity 'viral proteins' named entity 'Middle East respiratory syndrome'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software